Trial Profile
Frontline treatment with gemcitabine, oxaliplatin and erlotinib for the treatment of advanced or metastatic pancreatic cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Dec 2015
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Gemcitabine; Oxaliplatin
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 15 Dec 2015 New trial record